How to prepare a pediatric study waiver request

How do you support a pediatric study waiver request?

Identify the applicable assessment or investigation, the precise age groups and the criterion supporting full or partial relief. Present affirmative evidence, limitations and the plan for groups outside the request. Keep a planned waiver in the iPSP distinct from FDA’s formal decision at application approval; convenience, missing data or a competitor’s waiver do not establish your product’s waiver.

Before you begin

PREA pediatric assessment or applicable molecularly targeted pediatric cancer investigation waiver requests; not an exemption from informed consent.

What you will prepare: An evidence-backed waiver rationale for the specified age groups and indication.

Name the age group and the waiver criterion

A waiver asks for relief from an applicable pediatric assessment or investigation; a deferral asks for later delivery. First establish what applies to the product. Then identify whether the requested waiver covers all relevant pediatric groups or only named groups.

FDA's final iPSP guidance, V.B.4, discusses statutory criteria including studies that are impossible or highly impracticable; evidence strongly suggesting ineffectiveness or lack of safety; and the combined finding of no meaningful therapeutic benefit over existing therapies and no likely substantial pediatric use. The inability to produce a necessary pediatric formulation after reasonable attempts is a distinct partial-waiver consideration. Do not shorten the combined therapeutic-benefit/use criterion to “better treatments exist.” The May 2023 regulatory-considerations document remains draft guidance.

Prepare a rationale that can be checked

Use a separate rationale for each affected group. For impracticability, collect disease frequency, diagnostic feasibility, geographic distribution and realistic recruitment evidence. Explain why those facts prevent a useful study rather than merely make it inconvenient. For an ineffective or unsafe-use argument, identify the relevant findings, exposure, age relationship and scientific limitations. Route any labeling consequences to the labeling owner.

For a formulation-based partial request, collect the actual development attempts, constraints, results and alternatives examined. A preference not to develop a formulation is not evidence of failed reasonable attempts. Show whether the problem affects every proposed pediatric age group or only one.

An editorial outline is: request and scope; applicable criterion; evidence summary; counterevidence and limitations; prior FDA discussion; impact on the remaining pediatric plan; indexed supporting references. Keep proposal language separate from the final decision.

Reconcile the plan with the formal marketing-application request

The iPSP can contain a planned waiver request and receive feedback. The final guidance explains that formal waiver decisions are made at marketing-application approval. Carry the current rationale into the application instead of attaching an old planning paragraph without review. New disease, safety or formulation information can change the argument.

For oncology programs, establish the applicable statute and application date before assuming an adult-only disease or orphan designation resolves the question. Refer to the pediatric-administration guide for the 2026 statutory transition. Record evidence that changes the proposed disposition; do not turn an incomplete applicability assessment into a requested full waiver.

Worked review: one unsupported age-group conclusion

Fictional editorial exercise: a request seeks a full waiver because the team found very few infants with the condition. The same source describes a material adolescent population.

Split the age groups and reassess the rationale. The infant observation cannot support a full pediatric conclusion. If the literature search method or population denominator is missing, obtain it before writing that studies are impracticable. The deliverable should show the evidence for each requested group and the plan for groups outside the waiver.

Match each waiver argument to the evidence it needs

Write one rationale for each affected age group and indication. Use the following comparison to check that the evidence addresses the actual criterion rather than a looser commercial or operational concern.

The formulation basis is a partial-waiver consideration. Explain which age group needs the formulation and why the documented failure concerns that group. Do not extend a problem with infant administration to adolescents who could use an appropriate available formulation without assessing that difference.

For a feasibility argument, distinguish disease prevalence, the trial-eligible population and achievable recruitment. A prevalence estimate may include patients who cannot meet the proposed criteria; a site's estimate may omit other feasible sites. State the source dates, assumptions and uncertainty. The aim is not to make recruitment look difficult, but to explain why the necessary study meets the requested criterion.

Counterevidence exercise: the request cites a very small population from one country, while a newer registry identifies additional patients elsewhere. Assess the registry’s disease definition, age coverage and relevance to a feasible study. Address its implications explicitly. Ignoring it would weaken the argument; assuming that every registered patient is recruitable would also overstate the evidence.

A waiver for another drug in the class can provide supportive context under the final guidance. It is not the decision for this drug, and a different formulation, indication or age range can change the assessment. For an ineffective or unsafe-use basis, the guidance also identifies labeling consequences. Coordinate that information rather than treating relief from a study as permission to omit the underlying safety concern.

Return to the pediatric plan to reconcile remaining studies and proposal status. If the evidence supports later completion rather than relief, assess a deferral request. Do not treat delay and waiver as alternative labels for the same unsupported conclusion.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides